Today: 21 May 2026
Browse Category

ASX:WJL 19 November 2025

Stock Market Today

  • Metal Bank Raises A$1.2 Million at 30% Premium, Signaling Confidence in Gold Assets
    May 20, 2026, 9:21 PM EDT. Metal Bank (ASX:MBK) secured A$1.2 million through a share placement at A$0.017, a 30% premium over the May 12 close of A$0.013. This rare premium in the ASX microcap gold sector indicates cornerstones see undervalued potential in its Seven Leaders and Livingstone projects. The funds will support mining development and drilling aimed at upgrading resources at these deposits. Metal Bank plans to use a portable gravity gold recovery system, avoiding costly carbon-in-leach (CIL) processing, reducing capital expenditure and dilution risk. The company's resources include 2.81 million tonnes at 1.36 grams per tonne for 122,500 ounces of gold. Market watchers await execution to validate the optimistic outlook reflected in the premium placement.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop